Results 31 to 40 of about 10,142,751 (308)

Disease-free survival (DFS) among 30 patients with triple-negative breast cancer (TNBC).

open access: yes, 2022
Disease-free survival (DFS) among 30 patients with triple-negative breast cancer (TNBC).
Dalia O. Mohamed (11978982)   +6 more
core   +1 more source

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials

open access: yesBMC Cancer, 2020
Background We aimed to assess whether disease-free survival (DFS) could serve as a reliable surrogate endpoint for overall survival (OS) in adjuvant trials of pancreatic cancer.
Run-Cong Nie   +12 more
doaj   +1 more source

Disease-free survival curves for patients with mutations.

open access: yes, 2016
(A) TP53 and (B) MYD88 genes After applying multiple comparison by using FDR, TP53 and MYD88 showed a tendency for shorter disease-free survival (P = 0.054, both).
JooRyung Huh (3396479)   +11 more
core   +1 more source

Effects of BMI on prognosis , disease-free survival and overall survival of breast cancer

open access: yesBMC Cancer
Abstract Background Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is unclear. This study aimed to investigate different effects of Body Mass Index (BMI) on prognosis disease-free survival and overall survivor of breast cancer patients.
Vahid Zangouri   +7 more
openaire   +3 more sources

Cyclin D3 predicts disease-free survival in breast cancer [PDF]

open access: yesCancer Cell International, 2015
Cyclin D3, which induces progression through the G1 phase of the cell cycle, is a regulator of Cyclin-dependent kinases 4 and 6. Previous studies revealed that abnormal expression of Cyclin D3 was found in many different cancers. However, the role of Cyclin D3 in breast cancer (BC) remains unknown.
Chi, Yayun   +5 more
openaire   +2 more sources

Tumor budding as a predictor of disease-free survival in patients with cholangiocarcinoma

open access: yesPathology and Oncology Research, 2023
Background: Tumor budding is considered a prognostic factor in several solid cancer types. However, we lack comprehensive information on the importance of tumor budding in cholangiocarcinoma. Therefore, we aimed to assess the prognostic value of tumor budding in intrahepatic and extrahepatic cholangiocarcinomas and to evaluate its correlations with ...
Kyung Bin Kim   +13 more
openaire   +3 more sources

Ovarian Sex Cord Stromal Tumors in Children and Adolescents—The European Standard Clinical Practice Recommendations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider   +15 more
wiley   +1 more source

High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer

open access: yesCancer Cell International, 2019
Background Enhanced glycolysis in tumors, known as the Warburg effect, provides the metabolic basis of enhanced cancer cell proliferation and metastasis.
Ling Yao   +4 more
doaj   +1 more source

Survival Rate of Patients with Squamous Cell Carcinoma of Larynx Undergoing Nonsurgical Treatments and Radiotherapy, From 2003 to 2015 [PDF]

open access: yesJournal of Kerman University of Medical Sciences, 2020
Background:The incidence rate of head and neck cancer in the world is about 560,000 new cases a year. Larynx cancer is the most common malignancy in head and neck in Iran.
Mohammad Hasan Larizadeh   +3 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy